ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

ACADIA Pharma reports robust Q3 earnings and outlines growth strategies

ACADIA Pharma's Q3 earnings reflect strong sales performance, a robust financial position, and a focus on advancing its pipeline assets for future growth.
The company's new CEO brings industry expertise and a vision for expansion, while challenges in market expansion and competition require strategic planning.
Opportunities for ACADIA Pharma lie in international expansion, pipeline development, and continued efforts to drive growth through effective commercial strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

After a nice close to 2020, Acadia's shares hit a slick spot in 2021.When they are waxing, as they so often do, Acadia's shares are good candidates for selling covered calls.

Acadia: Waxing And Waning Into A Big PDUFA

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to assume the role of chief executive officer at another healthcare company. Charmaine Lykins, Senior Vice President, Global Product Planning and Chief Marketing Officer and Amanda Morgan, Senior Vice President, Chief Revenue and Customer Officer, will lead the commercial organ

Acadia Pharmaceuticals Announces Commercial Leadership Change

ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Stephen Davis at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc.

Shuman Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 2:00 p.m. Eastern Time, followed by a question and answer session. The conference will be held virtually. A live audio-only webcast of Acadia's presentation and question and answer session, along with accompanying slides, will be accessible on the company's website, www.acadia-pharm.com, under the invest

Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

Neurocrine Biosciences

uniQure

Vertex Pharmaceuticals

Zogenix

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Why Is Acadia (ACAD) Up 9.7% Since Last Earnings Report?

CVS Health

Healthcare Realty Trust Inc

The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.

Raymond James Top Health Care Picks Crushing S&P 500: 4 Stocks to Buy Now

Acadia Healthcare

Let's see if Acadia Healthcare (ACHC) stock is a good choice for value-oriented investors right now from multiple angles.

Is Acadia Healthcare (ACHC) a Good Value Investor Stock Now?

ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through December 15, 2020. About Acadia Pharmaceuti

Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid.

ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

The good news? Sales of Nuplazid are soaring.

What's Behind Acadia Pharmaceuticals' Mixed Q3 Results

ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020. “This quarter we drove strong performance through the continued growth of new prescribers with more patients benefitting from NUPLAZID® treatment for their Parkinson's dise

Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results

Alnylam Pharmaceuticals

AvroBio Inc

Biohaven Pharmaceutical Hld

BioNTech SE

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

The company's latest quarterly update impressed investors.

Why Acadia Healthcare Stock Is Soaring Today

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) changed recently.

Were Hedge Funds Wrong About Embracing ACADIA Pharmaceuticals Inc. (ACAD)?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020. Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patient

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada

Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020

Alkermes

Arrowhead Pharmaceuticals

BioMarin Pharmaceutical

Ionis Pharma

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies that have shown strong historical revenue growth, improving fundamentals, and yet have not rallied.

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs. “Dr. Garofalo is a highly-regarded business leader and innovator with invaluable clinical development experience,” said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia’s Board of Directors. “We are e

Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Steve Davis Presents at Cantor Virtual Global Healthcare Conference (Transcript)

Morgan Stanley

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

News for ACADIA Pharma Stock (ACAD)